ClinicalTrials.gg

Program

MVA-BN smallpox vaccine

Also written as “IMVAMUNE”, “IMVAMUNE (MVA-BN)” and “IMVAMUNE®”.

Its studies are mostly in Smallpox · Mpox, Monkeypox · Dermatitis, Atopic · HIV Infections, led by 3 companies.

Furthest: phase 4, since Mar 5, 201816 company-led studies, 2 open or runningNext primary completion: Nov 30, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bavarian Nordic142 open or runningphase 4since Mar 5, 2018Sep 11, 2005Nov 30, 2026phase 2 · NCT07199569
Johnson & Johnson10 open or runningearly phase 1since Apr 1, 2019Apr 1, 2019none ahead
Sanofi10 open or runningphase 2since Apr 25, 2007Apr 25, 2007none ahead

Also a collaborator on its studies: ICON.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 11, 2005First studies: 2 phase 2 studiesNew to Bavarian NordicBavarian Nordic · NCT00189956, NCT00189904
  2. Sep 11, 20052 phase 1 studiesBavarian Nordic · NCT00189917, NCT00189943
  3. Apr 19, 20063 phase 2 studiesBavarian Nordic · NCT00316589, NCT00316524, NCT00316602
  4. Apr 25, 2007Sanofi’s first study: phase 2 study in SmallpoxNew to SanofiSanofi · NCT00466245 · 590 enrolled
  5. May 27, 2008Phase 2 study in SmallpoxBavarian Nordic · NCT00686582 · 304 enrolled · Germany
  6. Mar 5, 2009Phase 2 study in SmallpoxBavarian Nordic · NCT00857493 · 120 enrolled · United States
  7. Jun 14, 2010Phase 3 study in SmallpoxBavarian Nordic · NCT01144637 · 4,005 enrolled · United States
  8. Jan 15, 2014Phase 2 study in SmallpoxBavarian Nordic · NCT02038881 · 87 enrolled · United States, Puerto Rico
  9. Mar 5, 2018Phase 4 study in VaccinationBavarian Nordic · NCT03472014 · 22 enrolled · United States
  10. Apr 1, 2019Johnson & Johnson’s first study: early phase 1 study in HealthyNew to Johnson & JohnsonJohnson & Johnson · NCT03953196 · 48 enrolled · Belgium
  11. Jul 31, 2024Phase 2 study in Mpox, MonkeypoxBavarian Nordic · NCT06549530 · 460 enrolled · Democratic Republic of the Congo, Uganda
  12. Sep 22, 2025Phase 2 study in Mpox, MonkeypoxBavarian Nordic · NCT07199569 · 970 enrolled · United States

Ahead

  1. Nov 30, 2026Primary completion: phase 2 study in Mpox, MonkeypoxBavarian Nordic · NCT07199569

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“A vaccine consisting of modified vaccinia Ankara-Bavarian Nordic (MVA-BN), a live, attenuated, non-replicating, proprietary version of the MVA virus, used for the prevention of smallpox and monkeypox, ”NCIt, by rule

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07199569Mpox, Monkeypox · United States2Active, not recruitingBavarian NordicNov 30, 2026970
NCT06549530Mpox, Monkeypox · Democratic Republic of the Congo, Uganda2Active, not recruitingBavarian NordicMay 1, 2026460
NCT03953196Healthy · BelgiumEarly 1CompletedJohnson & JohnsonDec 26, 201948
NCT03472014Vaccination · United States4CompletedBavarian NordicNov 14, 201422
NCT02038881Smallpox · United States, Puerto Rico2CompletedBavarian NordicMay 10, 201787
NCT01144637Smallpox · United States3CompletedBavarian NordicNov 20134,005
NCT00857493Smallpox · United States2CompletedBavarian NordicAug 2010120
NCT00686582Smallpox · Germany2CompletedBavarian NordicDec 2008304
NCT00466245Smallpox2CompletedSanofiJun 2006590
NCT00316602Dermatitis, Atopic · United States, Mexico2CompletedBavarian NordicNov 2009632
NCT00316589HIV Infections · United States, Puerto Rico2CompletedBavarian NordicMar 2009581
NCT00316524Smallpox · Germany2CompletedBavarian NordicFeb 2007745
NCT00189943Smallpox · Germany1CompletedBavarian Nordic90
NCT00189956Smallpox · Switzerland2CompletedBavarian NordicNov 2003165
NCT00189917Dermatitis, Atopic · Germany1CompletedBavarian NordicDec 200560
NCT00189904HIV Infections · United States2CompletedBavarian Nordic151

How it is read

Names in the registry

  • “IMVAMUNE”, 5 entries
  • “IMVAMUNE (MVA-BN)”, 4 entries
  • “IMVAMUNE®”, 3 entries
  • “MVA-BN”, 2 entries
  • “MVA-BN (Quail)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.